


**Figure S1.** Funnel Plot for assessment of publications bias based on primary outcome (CDR-SB) effect sizes




**Figure S2.** Forest plots of (a) Mini Mental State Examination (MMSE) and (b) Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) meta-analyses with subgroup analyses by drug




**Figure S3.** Forest plot of CSF p181-tau meta-analysis with subgroup analysis by drug




**Figure S4.** Forest plot of CSF $A\beta_{42}$ meta-analysis with subgroup analysis by drug




**Figure S5.** Forest plot of CSF $A\beta_{40}$ meta-analysis with subgroup analysis by drug




**Figure S6.** Forest plot of all-cause mortality meta-analysis with subgroup analysis by drug




**Figure S7.** Forest plots of (a) Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) and (b) AD Assessment Scale–Cognitive Subscale (ADAS-Cog) meta-analyses with with subgroup analyses by binding affinity to Aβ monomers




**Figure S8.** Forest plots of (a) Mini Mental State Examination (MMSE) and (b) Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) meta-analyses with subgroup analyses by binding affinity to Aβ monomers




**Figure S9.** Forest plots of (a) Amyloid PET and (b) CSF p181-tau meta-analyses with subgroup analyses by binding affinity to Aβ monomers




**Figure S10**. Forest plot of CSF $A\beta_{42}$ meta-analysis with subgroup analysis by monomer binding affinity




**Figure S11.** Forest plot of CSF $A\beta_{40}$ meta-analysis with subgroup analysis by monomer binding affinity

(a)




(b)




**Figure S12.** Forest plots of (a) Amyloid-Related Imaging Abnormalities with Edema/Effusion (ARIA-E) and (b) ARIA with microhemorrhages or superficial siderosis (ARIA-H) with subgroup analyses by binding affinity to Aβ monomers




**Figure S13.** Forest plot of all-cause mortality meta-analysis with subgroup analysis by monomer binding affinity




**Figure S14.** Forest plots of (a) Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), (b) AD Assessment Scale–Cognitive Subscale (ADAS-Cog), (c) AD Cooperative Study – Activities of Daily Living (ADCS-ADL), (d) Mini Mental Examination State (MMSE) meta-analyses of FDA-approved monoclonal antibodies only with subgroup analyses by drug

(a)




(b)




(c)




**Figure S15.** Forest plots of (a) Amyloid PET, (b) CSF p181-tau, (c) CSF $A\beta_{42}$ meta-analyses of FDA-approved monoclonal antibodies only with subgroup analyses by drug

(a)




(b)




**Figure S16.** Forest plots of (a) Amyloid-Related Imaging Abnormalities with Edema/Effusion (ARIA-E) and (b) ARIA with microhemorrhages or superficial siderosis (ARIA-H) meta-analysis of FDA-approved antibodies only with subgroup analyses by drug




**Figure S17.** Forest plots of all-cause mortality meta-analysis of FDA-approved antibodies only with subgroup analyses by drug